About GI stool testing
Normal gastrointestinal (GI) functioning is essential for digestion as well as for the removal of body waste and pathogens. GI disorders are a common problem in the general population. These disorders are known to cause severe harm to the health and quality of life of an individual. These disorders include malabsorption disorders, inflammatory bowel diseases, cancer of the digestive system, colitis, and gastroenteritis. Globally, about 1.7-2 billion cases of diarrheal diseases occur every year. Also, about 1,700 million cases of C. difficile infections have been reported worldwide every year.
Stool tests are used for the diagnosis of GI disorders and help detect parasite infection, inflammation, bleeding obstruction, and tumors in the GI tract and digestive system. The diagnosis of GI diseases is commonly done through laboratory tests using antigen or culture detection from stool samples. A stool test is of two categories: fecal occult blood test (FOBT) and clinical microbiological stool tests. These tests are either antibody-based or microbial particle-based detection methods, which include immunoassay, CLIA, and molecular diagnostic testing. Stool tests are used for the screening of colorectal cancer as well as the detection of pathogens such as C. difficile, H. pylora, Rotavirus, and Adenovirus.
The global GI stool testing market is expected to grow at a CAGR of 7.37% during 2014-2019.
Covered in this report
In this report, Technavio covers the present scenario and growth prospects of the global GI stool testing market for 2015-2019. To calculate the market size, we consider revenue generated from the sales of the following products:
• FOBT
• Clinical microbiology stool test
Technavio's report, Global GI Stool Testing Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape of the global BI and analytics platform market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.
Key regions
• Americas
• APAC
• EMEA
Key vendors
• Clinical Genomics
• Diasorin
• Meridian Bioscience
• Quidel
Other prominent vendors
• Alere
• Beckman Coulter
• bioMérieux
• Bio-Rad Laboratories
• CARE Products
• Cenogenics
• EIKEN CHEMICAL
• Epigenomics
• Epitope Diagnostic
• Exact Sciences
• Helena Laboratories
• Hemosure
• Mobidiag
• Orion Diagnostica
• Pinnacle BioLabs
• Polymedco
• Propper Manufacturing
• ScheBo Biotech
• Trinity Biotech
Key market driver
• Increased incidence of C. difficile infections
• For a full, detailed list, view our report
Key market challenge
• Accurate diagnostic testing
• For a full, detailed list, view our report
Key market trend
• Focus on rapid and early diagnosis
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
PART 01: Executive summary
Highlights
PART 02: Scope of the report
Market overview
Top-vendor offerings
PART 03: Market research methodology
Research methodology
Economic indicators
PART 04: Introduction
Key market highlights
PART 05: Market landscape
Market overview
Market size and forecast
Five forces analysis
PART 06: Reimbursement and coverage: An overview
Current scenario: Validating diagnostic tests
Reimbursement structure in the US
Reimbursement structure in EU
Prevailing issues of reimbursement policies
PART 07: Gastrointestinal stool tests: Present and future technology
PART 08: Market segmentation by product
Reagents
Instruments
PART 09: Market segmentation by application
Colorectal cancer
Diarrhea
Gastrointestinal tract infections
Others
PART 10: Market segmentation by technology
PART 11: Market segmentation by test
PART 12: Geographical segmentation
Global gastrointestinal stool testing market segmentation by geography
Gastrointestinal stool testing market in Americas
Gastrointestinal stool testing market in EMEA
Gastrointestinal stool testing market in APAC
PART 13: Market drivers
Increased incidence of Clostridium difficile infections
Automation and system integration
Early diagnosis of colorectal cancer
Focus on emerging countries
PART 14: Impact of drivers
PART 15: Market challenges
Accurate diagnostic testing
Business and regulatory issues
Alternatives to stool tests
PART 16: Impact of drivers and challenges
PART 17: Market trends
Rapid and early diagnosis
Use of point-of-care tests
Increase in public awareness
PART 18: Vendor landscape
Competitive scenario
Market share analysis 2014
Other prominent vendors
PART 19: Key vendor analysis
Clinical Genomics
DiaSorin
Meridian Bioscience
Quidel
PART 20: Appendix
List of abbreviations
PART 21: Explore Technavio
List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Global gastrointestinal stool testing market ($ millions)
Exhibit 03: Reimbursement perspectives of healthcare entities
Exhibit 04: Global gastrointestinal stool testing market segmentation by product
Exhibit 05: Global gastrointestinal stool testing market segmentation by product 2014
Exhibit 06: Global gastrointestinal stool testing market segmentation by application
Exhibit 07: Global gastrointestinal stool testing market segmentation by technology
Exhibit 08: Global gastrointestinal stool testing market segmentation by test
Exhibit 09: Global gastrointestinal stool testing market segmentation by geography 2014
Exhibit 10: Global gastrointestinal stool testing market segmentation by geography 2019
Exhibit 11: Global gastrointestinal stool testing market by geography 2014-2019
Exhibit 12: Gastrointestinal stool testing market in Americas ($ millions)
Exhibit 13: Gastrointestinal stool testing market in EMEA ($ millions)
Exhibit 14: Gastrointestinal stool testing market in APAC ($ millions)
Exhibit 15: Healthcare spending by country 2015 ($ billions)
Exhibit 16: Impact of drivers
Exhibit 17: Impact of drivers and challenges
Exhibit 18: Clinical Genomics: Key takeaways
Exhibit 19: DiaSorin: Key takeaways
Exhibit 20: Meridian Bioscience: Key takeaways
Exhibit 21: Quidel: Key takeaways
Exhibit 22: Clinical Genomics: Product categories
Exhibit 23: DiaSorin: Business segmentation by revenue 2014
Exhibit 24: DiaSorin: Business segmentation by revenue 2013 and 2014
Exhibit 25: DiaSorin: Geographical segmentation by revenue 2014
Exhibit 26: Meridian Bioscience: Business segmentation by revenue 2014
Exhibit 27: Meridian Bioscience: Business segmentation by revenue 2013 and 2014 ($ millions)
Exhibit 28: Meridian Bioscience: Geographical segmentation by revenue 2014
Exhibit 29: Quidel: Product segmentation by revenue 2014
Exhibit 30: Quidel: Product segmentation by revenue 2013 and 2014 ($ millions)
Exhibit 31: Quidel: Geographical segmentation by revenue 2014
